About Image


      Bone Biologics is a publicly traded company based in Burlington, MA and is focused on developing and marketing orthobiologic products. Our proprietary platform technology is NELL-1, a recombinant human protein growth factor that is essential for normal bone development. Our lead product is a NELL-1 based bone graft substitute for spine fusion, targeting the rapidly growing orthobiologics market. Our goal is to offer patients superior safety with uncompromising efficacy relative to existing technologies. NELL-1  provides specific targeted regulation over bone regeneration in the presence of targeted osteogenic cells, as both demonstrated in the lab and through the use of animal testing, unlike any other current therapy. It has been shown not to form bone when applied to non-osteogenic cells such as myoblasts (a type of embryonic progenitor cell that differentiates to give rise to muscle cells) nor does it induce adipogenesis (the formation of fat that can occur within the bone matrix often exhibited as cysts) that results in weaker bone.

      Our mission is to utilize the power of NELL-1 to improve clinical outcomes and reduce total health care delivery costs associated with spinal fusion. Bone Biologics is focused on bone repair and regeneration applications and is committed to exploring additional applications of the NELL-1 technology to enhance bone regeneration and repair in areas where the current options provide suboptimal patient outcomes.


      Leadership Image


          The Bone Biologics leadership team consists of some of the top leaders and innovators of orthobiologics in regenerative medicine. Not only does our leadership provide strategic oversight of the Company, they contribute to the collective advancement of the industry. This leadership is instrumental in fulfilling our mission to improve clinical outcomes and reduce health care delivery costs associated with lumbar spinal fusion.


          Products Image


              While Bone Biologics has chosen to focus its initial product development efforts in spinal fusion, we believe that this regenerative medicine technology has potential in the broader fields of bone regeneration and repair including osteoporosis, chondrocytes and applications using mesenchymal stem cells.


              Investor Relations

              Investor Relations Image

              Press Releases

              Current Press Releases

              News Archive

              Bone Biologics Adds Osteoporosis and Trauma Indications to its Portfolio

              BURLINGTON, Mass., August 23, 2017 — Bone Biologics Corp (OTC: BBLG), a developer of orthobiologic products for domestic and international spine fusion markets, today has announced that it has expanded its Field of Use definition of the license agreement with the UCLA Technology Development Group on behalf of UC Regents for NELL-1. Additionally, Bone Biologics has entered into an exclusive license agreement with the UCLA Technology Development Group on behalf of UC Regents for the worldwide application of the NELL-1 protein for both osteoporosis and trauma through a technology transfer.

              + Read More

              Bone Biologics Completes $1.4 Million Round of Financing

              BURLINGTON, Mass. August 22, 2017 — Bone Biologics (OTC: BBLG), a developer of orthobiologic products for domestic and international spine fusion markets, announced today the completion of a $1.4 million funding round with Musculoskeletal Transplant Foundation and Hankey Capital, LLC. The funding represents the first round of a previously announced private placement. Proceeds will be used for working capital, protein development, laboratory and testing equipment necessary to support such development, regulatory and clinical expenses, and development work to extend the patent life of NELL-1, as well as for other purposes not presently contemplated herein but which are related directly to growing the Company’s current business, research and development activities

              + Read More

              Bone Biologics Announces Appointment of Bret Hankey to Company’s Board of Directors

              BURLINGTON, Mass. August 3, 2017 — Bone Biologics Corp. (OTCQB: BBLG) announced that Bret Hankey has joined the company’s board of directors. Mr. Hankey brings more than 15 years of operating and board director experience to the BBLG board.

              + Read More

              Bone Biologics Corporation Announces Commencement of a Private Placement of Securities

              BURLINGTON, Mass. July 24, 2017 — Bone Biologics Corporation (OTCQB: BBLG) announced today that it has commenced a private offering of up to $10,000,000 of its securities. The securities will initially only be offered to persons who are either stockholders of the company or who are “accredited investors,” as defined in Regulation D under the Securities Act of 1933, as amended (the “Securities Act”). The net offering proceeds will be used for working capital including to fund the further development of Nell-1 which is a recombinant human protein growth factor essential for normal bone development.

              + Read More

              Older Entries »


              Contact Image


                  General Inquiries:
                  Chris Martin
                  412.749.9299 x2

                  Investor Inquiries:
                  Mark Collinson

                  Media Inquiries:
                  Tracy Williams
                  310.824.9000 x22

                  For information regarding our company and/or products, please complete the form below.

                  Your Name (required)



                  Email (required)


                  Preferred Means of Reply

                  Your Message

                  Scratch Pad
                  Parent : investor-relations 11